Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's disease

开发微流体人类神经血管单元系统来研究阿尔茨海默病的遗传和年龄相关危险因素

• 批准号: 10504196
• 负责人: Dritan Agalliu
• 金额: $ 120.15万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10504196
• 关键词: 3-Dimensional; Address; Advanced Glycosylation End Products; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease brain; Alzheimer' s disease pathology; Alzheimer' s disease risk; Amyloid; Astrocytes; Automobile Driving; Autopsy; Biochemical; Biological; Biological Process; Blood; Blood - brain barrier anatomy; Blood Vessels; Brain; CRISPR/Cas technology; Cell Line; Cell Nucleus; Cells; Cellular biology; Cerebrovascular Disorders; Cerebrum; Cognition; Data; Data Set; Databases; Development; Disease; Disease Progression; Early Onset Familial Alzheimer' s Disease; Economic Burden; Environment; Environmental Risk Factor; Etiology; Extracellular Matrix; Functional disorder; Future; Genetic; Genetic Risk; Genetic Transcription; Hand; Human; Image; Immune; Impaired cognition; Impairment; In Vitro; Knock-in; Knowledge Portal; Label; Late Onset Alzheimer Disease; Maintenance; Mediating; Memory impairment; Methodology; Microfluidics; Modeling; Molecular; Morphology; Mutation; Neurodegenerative Disorders; Pathogenesis; Pathogenicity; Pathology; Pathway interactions; Patients; Perfusion; Pericytes; Permeability; Persons; Phenotype; Plasma; Plasma Proteins; Play; Pluripotent Stem Cells; Population; Property; Proteasome Inhibitor; Prothrombin; Protocols documentation; Risk; Risk Factors; Role; Source; Structure; System; Therapeutic; Vascular Dementia; Vascular Diseases; Viral; age related; aged; blood-brain barrier function; brain endothelial cell; brain tissue; cell type; cerebrovascular; cohort; disease-causing mutation; effective therapy; efficacy evaluation; endothelial stem cell; executive function; familial Alzheimer disease; genetic risk factor; health economics; human data; human pluripotent stem cell; in vivo; innovation; microphysiology system; mutant; neurovascular unit; novel; response; risk variant; single-cell RNA sequencing; tau aggregation; therapeutic target; transcription factor; transcriptome; transcriptome sequencing; transcriptomics; transdifferentiation

PROJECT SUMMARY Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with severe impairment of memory, cognition and executive functions that has a tremendous health and economic burden. The lack of effective treatments to halt AD pathology necessitates development of human brain microphysiological systems to understand disease pathogenesis and develop potential therapeutics. Neurovascular unit (NVU) and blood-brain barrier (BBB) dysfunction play a key etiological role in AD progression; yet the contribution of genetic versus environmental risk factors for brain microvascular damage is unclear. In response to RFA (# PAR-20-055) this project will generate validated human pluripotent stem cells (PSC)-derived NVU cells, develop a perfused NVU 3D microphysiological system with plasma or blood from young or aged patients and compare its transcriptome profiles with the human AD brain vasculome to dissect the contribution of genetic versus age-related factors in AD. In preliminary studies, we have used CRISPR/Cas9 methodology to knock-in FAD or LOAD mutations in control PSC cell lines, developed strategies to differentiate PSC into brain microvascular endothelial cells (BMECs), pericytes or astrocytes and build brain-on-a-chip models with NVU cells and flow. In addition, our preliminary single nucleus RNA-seq of 24 human control and AD brains has identified 4 distinct BMEC populations, at the transcriptome level, one of which is positively correlated with cognitive impairment, Ab and tau accumulation. We hypothesize that synergistic interactions between genetic and environmental risk factors impair NVU function and BBB properties by altering key cellular pathways or transcription factors. We will address this hypothesis with three aims. In Aim 1, we will optimize protocols to generate BMECs via transdifferentiation from either endothelial progenitor cells or ECs, verify their molecular identity with single cell RNA-seq and validate their biological function using cellular, biochemical, imaging and functional approaches. We will incorporate BMECs into an NVU 3D microphysiological system along with hPSC-derived pericytes and astrocytes and compare cell biological, transcriptome, imaging and functional barrier properties between NVUs carrying AD-associated risk genes and isogenic controls. In Aim 2, we will leverage the data from the AMP-AD database to identify the AD brain vasculome-specific profiles associated with cognitive impairment, Ab and tau accumulation and evaluate whether AD-associated brain vasculome changes in vivo are present in the NVU 3D microphysiological system derived from hPSC lines carrying AD-associated risk genes. Finally in Aim 3, we will assess whether treatment with proteasome inhibitors that mimick loss of proteostatis, agents that produce advanced glycation end products, or dynamic flow of aged blood alters the morphology and transcriptome profiles of NVU cells and BBB transport. The proposed studies will establish a novel perfused blood/NVU 3D microphysiological system that will allow us to leverage its relevance to changes in the AD brain vasculome and examine interactions between genetic and environment factors for AD vascular pathology.

项目摘要 阿尔茨海默病（AD）是一种进行性神经退行性疾病，伴有严重的记忆障碍， 认知和执行功能，有巨大的健康和经济负担。缺乏有效 阻止AD病理学的治疗需要开发人脑微生理系统， 了解疾病的发病机制，开发潜在的治疗方法。神经血管单位（NVU）和血脑 血脑屏障（BBB）功能障碍在AD进展中起着关键的病因作用;然而，遗传与 脑微血管损伤的环境危险因素尚不清楚。针对RFA（# PAR-20-055）， 该项目将产生经过验证的人类多能干细胞（PSC）衍生的NVU细胞，开发灌注的NVU 3D微生理系统与年轻或老年患者的血浆或血液，并比较其转录组 人类AD脑血管组的特征，以剖析遗传与年龄相关因素在AD中的作用。 AD.在初步研究中，我们使用CRISPR/Cas9方法敲入FAD或LOAD突变， 对照PSC细胞系，开发了将PSC分化为脑微血管内皮细胞的策略 （BMEC）、周细胞或星形胶质细胞，并用NVU细胞和流动构建脑芯片模型。另外我们 24个人类对照和AD脑的初步单核RNA-seq鉴定了4种不同的BMEC 人群，在转录组水平，其中之一是正相关的认知障碍，抗体和 tau积累。我们假设遗传和环境风险因素之间的协同作用 通过改变关键细胞通路或转录因子来损害NVU功能和BBB特性。我们将 从三个方面来探讨这一假设。在目标1中，我们将优化协议以通过以下方式生成BMEC： 从内皮祖细胞或EC转分化，验证它们与单个细胞的分子同一性 RNA-seq，并使用细胞，生物化学，成像和功能方法验证其生物学功能。 我们将BMEC与hPSC衍生的周细胞一起沿着纳入NVU 3D微生理系统， 星形胶质细胞和比较NVU之间的细胞生物学，转录组，成像和功能屏障特性 携带AD相关风险基因和同基因对照。在目标2中，我们将利用AMP-AD的数据 数据库，以确定与认知障碍、Ab和tau相关的AD脑血管特异性谱 累积，并评价NVU 3D中是否存在AD相关的体内脑血管组变化 微生理学系统衍生自携带AD相关风险基因的hPSC系。在目标3中，我们将 评估是否用蛋白酶体抑制剂治疗，模拟蛋白酶抑制剂的损失， 晚期糖基化终产物或老化血液的动态流动改变了形态和转录组 NVU细胞和BBB运输的概况。拟议的研究将建立一种新的灌注血液/NVU 3D 微生理系统，这将使我们能够利用其与AD脑血管组变化的相关性， 研究AD血管病理学的遗传和环境因素之间的相互作用。